ReviewEye (London, England)2017
Assessing retinal ganglion cell damage.
Review in Eye (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 64 citations in OpenAlex.
- Longitudinal OCT changes of the peripapillary RNFL after different glaucoma interventions - a comparative study.BMC ophthalmology · 2026Article
- Brain-heart-eye axis revealed by multi-organ imaging genetics and proteomics.Nature biomedical engineering · 2026Article
- Comparison of Deep Learning Tools for Optic Nerve Axon Quantification Finds Limited Generalizability Upon Independent Validation.Bioengineering (Basel, Switzerland) · 2026Article
- Comparison of Deep Learning Tools for Optic Nerve Axon Quantification Finds Limited Generalizability on Independent Validation.bioRxiv : the preprint server for biology · 2026Article
- Integrated visible-light optical coherence tomography and fluorescence scanning laser ophthalmoscopy to image retinal ganglion cell axons.Biomedical optics express · 2025Article
- SVM-Based Optical Detection of Retinal Ganglion Cell Apoptosis.Photonics · 2025Article
- Fluorescent identification of axons, dendrites and soma of neuronal retinal ganglion cells with a genetic marker as a tool for facilitating the study of neurodegeneration.FASEB bioAdvances · 2025Article
- A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity.Nature neuroscience · 2024Article
- Hereditary Optic Neuropathies: A Systematic Review on the Interplay between Biomaterials and Induced Pluripotent Stem Cells.Bioengineering (Basel, Switzerland) · 2024Review
- Biometry extraction and probabilistic anatomical atlas of the anterior Visual Pathway using dedicated high-resolution 3-D MRI.Scientific reports · 2024Article
- Article
- Morphological disruption and visual tuning alterations in the primary visual cortex in glaucoma (DBA/2J) mice.Neural regeneration research · 2024Article
- Inflammatory mechanisms contributing to retinal alterations in HIV infection and long-term ART.Southern African journal of HIV medicine · 2024Review
- Unleashing the potential of CRISPR multiplexing: Harnessing Cas12 and Cas13 for precise gene modulation in eye diseases.Vision research · 2023Review
- Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium.Molecular neurodegeneration · 2023Review
- Longitudinal Analysis of Retinal Ganglion Cell Damage at Individual Axon Bundle Level in Mice Using Visible-Light Optical Coherence Tomography Fibergraphy.Translational vision science & technology · 2023Article
- Diabetes has no additional impact on retinal ganglion cell loss in a mouse model of spontaneous glaucoma.European journal of ophthalmology · 2023Article
- Intraocular Pressure-Lowering and Retina-Protective Effects of Exosome-Rich Conditioned Media from Human Amniotic Membrane Stem Cells in a Rat Model of Glaucoma.International journal of molecular sciences · 2023Article
- Alteration of neurofilament heavy chain and its phosphoforms reveals early subcellular damage beyond the optic nerve head in glaucoma.Frontiers in neurology · 2023Article
- Glial cells as a promising therapeutic target of glaucoma: beyond the IOP.Frontiers in ophthalmology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal ganglion cell (RGC) loss is the hallmark of optic neuropathies, including glaucoma, where damage to RGC axons occurs at the level of the optic nerve head. In experimental glaucoma, damage is assessed at the axon level (in the retinal nerve fibre layer and optic nerve head) or at the soma level (in the retina). In clinical glaucoma where measurements are generally limited to non-invasive techniques, structural measurements of the retinal nerve fibre layer and optic nerve head, or functional measurements with perimetry provide surrogate estimates of RGC integrity. These surrogate measurements, while clinically useful, are several levels removed from estimating actual RGC loss. Advances in imaging, labelling techniques, and transgenic medicine are making enormous strides in experimental glaucoma, providing knowledge on the pathophysiology of glaucoma, its progression and testing new therapeutic avenues. Advances are also being made in functional imaging of RGCs. Future efforts will now be directed towards translating these advances to clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.